Pro Medicus (ASX:PME) - CEO Dr Sam Hupert
CEO Dr Sam Hupert
Source: Pro Medicus
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Pro Medicus (PME)’s wholly owned subsidiary has signed a $40 million contract with Novant Health
  • Visage Imaging penned a seven-year contract, which will see the company’s Visage 7 Enterprise Imaging Platform and Visage 7 Workflow module implemented throughout Novant Health
  • Planning for the rollout is set to start immediately, with launch dates targeted for the second half of the financial year, deployed on the Microsoft Azure cloud
  • Pro Medicus is down 1.1 per cent, trading at $54.01 at 12:20 pm AEST

Pro Medicus (PME)’s wholly owned subsidiary has signed a $40 million contract with Novant Health.

Visage Imaging penned the seven-year contract which will see the company’s Visage 7 Enterprise Imaging Platform and Visage 7 Workflow module implemented throughout Novant Health, providing a unified diagnostic imaging platform across the network.  

Planning ahead of the rollout is set to start immediately, with launch dates targeted for the second half of the financial year.

Pro Medicus CEO Sam Hupert explained the implementation would be fully deployed on the Microsoft Azure cloud.

“Novant Health is our seventh major North American contract in less than 18 months and our equal largest deal to date, underpinning the strong momentum we continue to build in the market,” Dr Hupert said.

Novant Health also joins an increasing number of clients to opt for a fully cloud-based solution.

“Our pipeline remains strong. Deals like this confirm our view that Visage 7, with its proven cloud native technology and modular design, provides us with a significant strategic advantage that enables us to address opportunities across a growing segment of the market both in North America and other regions,” Dr Hupert said.

Pro Medicus was down 1.1 per cent, trading at $54.01 at 12:20 pm AEST.

PME by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…